[Effectiveness of allogeneic peripheral blood stem cell transplantation in 23 patients with myelodysplastic syndromes].
OBJECTIVE
To analyse the outcome of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for myelodysplastic syndromes (MDS).


METHODS
Twenty-three patients with MDS received G-CSF mobilized HLA-identical sibling allo-PBSCT. The numbers of mononuclear cells (MNC) and CD34+ cells were 8. 25 (4.50 -22.36) x 10(8)/kg and 5.59 (1.57 - 12.22) x 10(6)/kg respectively. CsA and shorten course MTX were used for graft-versus-host disease (GVHD) prophylaxis and MMF was given on + 1 d - +28 d posttransplantation.


RESULTS
Among 23 patients, 22 achieved hematopoietic recovery. The median time of ANC > 1.0 x 10(9)/L and BPC > 50 x 10(9)/L were + 13 (+ 11 - +17) days and + 30 (+13 + 102) days respectively. Two patients died of transplant related complications and three died of disease relapse, while 18 patients survived. Kaplan-Meier analysis showed disease free survival and relapse rate were (77.8 +/- 8.7)% and (14.4 +/- 7.5)% respectively.


CONCLUSIONS
Allo-PBSCT is an effective treatment for MDS patients.
Hu
Liang-ding
LD
Hematopoietic Stem Cell Transplantation Center of PLA, Affiliated Hospital of Chinese Academy of Military Medical Sciences, Beijing, China.
Chen
Hu
H
Jiang
Min
M
Li
Bo-tao
BT
Qin
Mao-quan
MQ
Yu
Zhi-yong
ZY
Li
Yu-hang
YH
D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34; D017707:Erythrocyte Transfusion; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000601:surgery*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D018952:Antigens, CD34